<p><strong>大自然藥業公司</strong> (NASDAQ:UPC) 的股票在過去一個月表現糟糕，損失了 31%，而在此之前的表現相對較好。最近的下跌使得股東在過去一年中面臨災難性的損失，損失幅度達到 95%。</p>
<p>在價格大幅下跌後，考慮到幾乎一半的美國製藥行業公司市銷率（&#34;P/S&#34;）超過 4.1 倍，甚至市銷率超過 20 倍的情況並不罕見，當前的大自然藥業可能看起來是一個強有力的買入機會，其市銷率為 0.1 倍。然而，我們需要更深入地研究，以確定這種大幅降低的市銷率是否有合理的基礎。</p>
<p>特朗普承諾要&#34;釋放&#34;美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
<p>查看我們對大自然藥業的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/684099523-ps-multiple-vs-industry-1-dark-2/1764065756629?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/684099523-ps-multiple-vs-industry-1-dark-2/1764065756629"/></p>
<p>NasdaqCM:UPC 市銷率與行業比較 2025 年 11 月 25 日</p>
<h3>大自然藥業的表現如何</h3>
<p>舉個例子，過去一年中大自然藥業的收入有所下降，這並不是一個理想的情況。許多人可能預期這種令人失望的收入表現將繼續或加速，這抑制了市銷率。看好大自然藥業的人希望情況並非如此，以便他們能夠以較低的估值買入該股票。</p>
<p>我們沒有分析師的預測，但您可以通過查看我們對大自然藥業的 <strong>免費</strong> 報告，瞭解最近的趨勢如何為公司的未來鋪路，包括收益、收入和現金流。</p>
<h2>大自然藥業是否有收入增長的預測？</h2>
<p>有一個內在的假設，即公司應該遠遠低於行業表現，才能使像大自然藥業這樣的市銷率被認為是合理的。</p>
<p>在回顧過去一年的財務數據時，我們感到沮喪，因為公司的收入下降了 28%。過去三年的表現也不理想，公司總收入縮水了 60%。因此，可以公平地説，最近的收入增長對公司來説是不可取的。</p>
<p>與公司相比，行業的其他部分預計在未來一年將增長 23%，這確實讓公司的近期中期收入下降顯得更加突出。</p>
<p>鑑於此，理解大自然藥業的市銷率低於大多數其他公司的原因是可以理解的。然而，隨着收入的下滑，市銷率是否已經觸底並沒有保證。即使只是維持這些價格也可能很困難，因為最近的收入趨勢已經對股價造成了壓力。</p>
<h2>我們可以從大自然藥業的市銷率中學到什麼？</h2>
<p>大自然藥業的市銷率最近看起來和其股價一樣疲軟。雖然市銷率不應該是決定是否購買股票的唯一因素，但它確實是收入預期的一個有效晴雨表。</p>
<p>正如我們所懷疑的，我們對大自然藥業的調查顯示，其中期收入的下降正在導致其低市銷率，考慮到行業預計將增長。目前，股東們接受低市銷率，因為他們承認未來的收入可能不會帶來任何令人愉快的驚喜。除非近期的中期條件改善，否則它們將繼續在這些水平上形成股價的障礙。</p>
<p>始終需要考慮投資風險的潛在威脅。我們已識別出 <strong>大自然藥業的 4 個警示信號</strong>，理解這些信號應該是您投資過程的一部分。</p>
<p>重要的是要 <strong>確保您尋找的是一家優秀的公司，而不僅僅是您遇到的第一個想法。</strong> 如果持續盈利能力符合您對優秀公司的定義，請查看這份 <strong>免費</strong> 的有趣公司名單，這些公司最近的盈利增長強勁且市盈率較低。</p>

大自然藥業

<p>宇宙藥業公司 (NASDAQ:UPC) 的股價在一個月內下跌了 31%，過去一年累計損失達 95%。儘管市銷率僅為 0.1 倍，但去年收入下降了 28%，三年內下降了 60%，與行業預期的 23% 增長形成鮮明對比。公司的財務困境導致其股價低迷，且沒有立即改善收入的跡象</p>

<p><strong>Universe Pharmaceuticals INC</strong> (NASDAQ:UPC) shares have had a horrible month, losing 31% after a relatively good period beforehand. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 95% loss during that time.</p>
<div class="lb-trans"><p><strong>大自然藥業公司</strong> (NASDAQ:UPC) 的股票在過去一個月表現糟糕，損失了 31%，而在此之前的表現相對較好。最近的下跌使得股東在過去一年中面臨災難性的損失，損失幅度達到 95%。</p>
</div><p>Following the heavy fall in price, Universe Pharmaceuticals may look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 0.1x, considering almost half of all companies in the Pharmaceuticals industry in the United States have P/S ratios greater than 4.1x and even P/S higher than 20x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.</p>
<div class="lb-trans"><p>在價格大幅下跌後，考慮到幾乎一半的美國製藥行業公司市銷率（&#34;P/S&#34;）超過 4.1 倍，甚至市銷率超過 20 倍的情況並不罕見，當前的大自然藥業可能看起來是一個強有力的買入機會，其市銷率為 0.1 倍。然而，我們需要更深入地研究，以確定這種大幅降低的市銷率是否有合理的基礎。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承諾要&#34;釋放&#34;美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
</div><p>See our latest analysis for Universe Pharmaceuticals</p>
<div class="lb-trans"><p>查看我們對大自然藥業的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/684099523-ps-multiple-vs-industry-1-dark-2/1764065756629" alt="" original-src="https://images.simplywall.st/asset/chart/684099523-ps-multiple-vs-industry-1-dark-2/1764065756629"/></p>
<p>NasdaqCM:UPC Price to Sales Ratio vs Industry November 25th 2025</p>
<div class="lb-trans"><p>NasdaqCM:UPC 市銷率與行業比較 2025 年 11 月 25 日</p>
</div><h3>How Universe Pharmaceuticals Has Been Performing</h3>
<div class="lb-trans"><h3>大自然藥業的表現如何</h3>
</div><p>As an illustration, revenue has deteriorated at Universe Pharmaceuticals over the last year, which is not ideal at all. It might be that many expect the disappointing revenue performance to continue or accelerate, which has repressed the P/S. Those who are bullish on Universe Pharmaceuticals will be hoping that this isn't the case so that they can pick up the stock at a lower valuation.</p>
<div class="lb-trans"><p>舉個例子，過去一年中大自然藥業的收入有所下降，這並不是一個理想的情況。許多人可能預期這種令人失望的收入表現將繼續或加速，這抑制了市銷率。看好大自然藥業的人希望情況並非如此，以便他們能夠以較低的估值買入該股票。</p>
</div><p>We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our <strong>free</strong> report on Universe Pharmaceuticals' earnings, revenue and cash flow.</p>
<div class="lb-trans"><p>我們沒有分析師的預測，但您可以通過查看我們對大自然藥業的 <strong>免費</strong> 報告，瞭解最近的趨勢如何為公司的未來鋪路，包括收益、收入和現金流。</p>
</div><h2>Is There Any Revenue Growth Forecasted For Universe Pharmaceuticals?</h2>
<div class="lb-trans"><h2>大自然藥業是否有收入增長的預測？</h2>
</div><p>There's an inherent assumption that a company should far underperform the industry for P/S ratios like Universe Pharmaceuticals' to be considered reasonable.</p>
<div class="lb-trans"><p>有一個內在的假設，即公司應該遠遠低於行業表現，才能使像大自然藥業這樣的市銷率被認為是合理的。</p>
</div><p>In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 28%. The last three years don't look nice either as the company has shrunk revenue by 60% in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>在回顧過去一年的財務數據時，我們感到沮喪，因為公司的收入下降了 28%。過去三年的表現也不理想，公司總收入縮水了 60%。因此，可以公平地説，最近的收入增長對公司來説是不可取的。</p>
</div><p>In contrast to the company, the rest of the industry is expected to grow by 23% over the next year, which really puts the company's recent medium-term revenue decline into perspective.</p>
<div class="lb-trans"><p>與公司相比，行業的其他部分預計在未來一年將增長 23%，這確實讓公司的近期中期收入下降顯得更加突出。</p>
</div><p>In light of this, it's understandable that Universe Pharmaceuticals' P/S would sit below the majority of other companies. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. Even just maintaining these prices could be difficult to achieve as recent revenue trends are already weighing down the shares.</p>
<div class="lb-trans"><p>鑑於此，理解大自然藥業的市銷率低於大多數其他公司的原因是可以理解的。然而，隨着收入的下滑，市銷率是否已經觸底並沒有保證。即使只是維持這些價格也可能很困難，因為最近的收入趨勢已經對股價造成了壓力。</p>
</div><h2>What We Can Learn From Universe Pharmaceuticals' P/S?</h2>
<div class="lb-trans"><h2>我們可以從大自然藥業的市銷率中學到什麼？</h2>
</div><p>Universe Pharmaceuticals' P/S looks about as weak as its stock price lately. While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.</p>
<div class="lb-trans"><p>大自然藥業的市銷率最近看起來和其股價一樣疲軟。雖然市銷率不應該是決定是否購買股票的唯一因素，但它確實是收入預期的一個有效晴雨表。</p>
</div><p>As we suspected, our examination of Universe Pharmaceuticals revealed its shrinking revenue over the medium-term is contributing to its low P/S, given the industry is set to grow. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises either. Unless the recent medium-term conditions improve, they will continue to form a barrier for the share price around these levels.</p>
<div class="lb-trans"><p>正如我們所懷疑的，我們對大自然藥業的調查顯示，其中期收入的下降正在導致其低市銷率，考慮到行業預計將增長。目前，股東們接受低市銷率，因為他們承認未來的收入可能不會帶來任何令人愉快的驚喜。除非近期的中期條件改善，否則它們將繼續在這些水平上形成股價的障礙。</p>
</div><p>It's always necessary to consider the ever-present spectre of investment risk. We've identified <strong>4 warning signs with Universe Pharmaceuticals</strong>, and understanding these should be part of your investment process.</p>
<div class="lb-trans"><p>始終需要考慮投資風險的潛在威脅。我們已識別出 <strong>大自然藥業的 4 個警示信號</strong>，理解這些信號應該是您投資過程的一部分。</p>
</div><p>It's important to <strong>make sure you look for a great company, not just the first idea you come across.</strong> So if growing profitability aligns with your idea of a great company, take a peek at this <strong>free</strong> list of interesting companies with strong recent earnings growth (and a low P/E).</p>
<div class="lb-trans"><p>重要的是要 <strong>確保您尋找的是一家優秀的公司，而不僅僅是您遇到的第一個想法。</strong> 如果持續盈利能力符合您對優秀公司的定義，請查看這份 <strong>免費</strong> 的有趣公司名單，這些公司最近的盈利增長強勁且市盈率較低。</p>
</div>

投資者看不到大自然藥業公司（NASDAQ:UPC）隧道盡頭的曙光，導致股價下跌 31%